NCT06665971View on ClinicalTrials.gov

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

September 15, 2026

Study Completion Date

November 14, 2026

Conditions
Eosinophilic Esophagitis (EoE)
Interventions
DRUG

Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

Dosage form: Subcutaneous injection Dosage: 300 mg/ 2ml Dosage frequency: Once a week Duration: 12 weeks

Trial Locations (1)

92037

RECRUITING

University of California San Diego (UCSD) Health Medical center, La Jolla

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of California, San Diego

OTHER